Shijiazhuang Yiling Pharmaceutical Co,Ltd.
News
Home - News
News

Tongluo Chinese medicine news

Tongluo Chinese medicine becomes the main force in the prevention and treatment of chronic diseases, experts gather in Shijiazhuang to discuss the theory of collateral diseases
On June 1st, the Advanced Seminar on Prevention and Treatment of Chronic Diseases, which was sponsored by the Chinese Medicine Association and organized by the Chinese Traditional Medicine Association, was held in Yiling Health City, Shijiazhuang. Professor Jia Zhenhua, Dean of Yiling Hospital affiliated to Hebei Medical University, Liu De, Dean of the Nine-type Personality Research Institute and Tsinghua University, was invited to attend the event. He gave a wonderful academic report to more than 500 hospital directors and directors from all over the country. .
In recent years, chronic diseases such as coronary heart disease, cerebrovascular disease, arrhythmia, heart failure, and diabetes have become the primary problems that endanger people's health, and they show signs of increasing morbidity. The number of chronically ill patients in China is also increasing year by year. Relevant data show that there are more than 300 million people with chronic diseases in China, and the number of deaths from chronic diseases has accounted for 80% of the deaths due to illness in China. From the perspective of TCM theory, these diseases with long duration, repeated pain, and protracted dysfunction can be classified as collateral diseases. Under the guidance of the theory of collateral disease, we have developed a series of innovative drugs such as Tongxinluo Capsule, Shensong Yangxin Capsule, Qiqiangxin Capsule and Lianhua Qinglan Capsule, which have improved the level of clinical diagnosis and treatment and have become the prevention and treatment of chronic diseases. The main force."
As a leading figure in the theory of traditional Chinese medicine, Dr. Jia Zhenhua pointed out in the report entitled "Study on the prevention and treatment of vascular lesions by the theory of veins and collaterals" that the study of traditional Chinese medicine collaterals always follows the development rules of traditional Chinese medicine and promotes collateral diseases while referring to international standards. Theoretical innovation drives clinical efficacy and subject development. In the past ten years, a series of clinical research on a series of traditional Chinese medicine evidence-based medicines conducted by two academics of the Chinese Academy of Engineering, Wu Yiling, as the chief scientist, has attracted more and more Chinese and Western medical experts to join the research team. Six evidence-based studies were carried out around Shensong Yangxin Capsule. Among them, 465 clinical evidence-based studies conducted by Professor Huang Congxin, Department of Cardiology, Wuhan University People's Hospital, found that Shensong Yangxin effectively reduced the number of premature ventricular episodes. It can improve the heart function of patients; 333 clinical evidence-based studies conducted by Professor Cao Kehui from Jiangsu Provincial People's Hospital confirmed that Shensong Yangxin can improve the heart rate of patients while treating premature beats. This article has been accepted by international core journals.
Taking Qiangxinxin Capsule as the research object, Prof. Li Xinli from the First Affiliated Hospital of Nanjing Medical University presided over the evidence-based study and confirmed that Qiqiangxin Capsule can significantly reduce the serum amino terminal brain natriuretic peptide precursor (NT-proBNP) in patients with chronic heart failure. Level, increase the patient's 6-minute walking distance, improve the patient's symptoms and quality of life and improve the left ventricular ejection fraction (LVEF), and reduce the incidence of composite endpoint events. The results of the study are in the Journal of the American College of Cardiology (Impact Factor: 19.896). Publish and distribute the editorial comments.
Not long ago, the 1212 evidence-based research results led by Academician Zhang Yun of the Chinese Academy of Engineering pointed out that Tongxinluo Capsule can safely and effectively reduce carotid intima-media thickness, plaque area and vascular remodeling index, confirming Tongxinluo Capsule Targeting the role of interventional plaques to reduce the risk of cardiovascular events. Professor Jia Zhenhua mentioned a Western medicine expert in Beijing when he introduced the research. He found that his carotid artery stenosis reached 70% more than 20 years ago. Since then, he has been taking Tongxinluo Capsule. Now it is found that carotid plaque has disappeared. The effect of Tongxinluo capsule on plaque intervention is significant.
According to Zheng Jinwei, director of the China Bank Project Office for the Prevention and Treatment of Chronic Diseases (Lycome Diseases), since the launch of the "Crisis Disease (Lycomed Disease) Prevention and Control Bank of China" campaign since 2015, senior seminars, expert clinics, expert rounds, and chronic disease patients have been educated. It has 4,935 events, covering 29 provinces, municipalities and autonomous regions across the country, benefiting 434,000 clinical experts. This seminar aims to let more clinical experts understand the theoretical system of collateral disease theory to guide chronic disease prevention and control; understand and master the latest research progress of collaterals to prevent chronic diseases, and use it for the prevention and treatment of clinical chronic diseases. Through the health education of chronically ill patients and the popularization of the theory of collateral disease, the health awareness and health level of the majority of chronically ill patients are improved.

The experts present at the meeting said that this seminar not only allowed them to see the great synergy of the innovation of Chinese and Western medicine, but also provided a good opportunity for the exchange of Chinese and Western medicine for collateral diseases.

Tongxinluo Capsule Lianhua Qinglan Capsule